PAVmed Adds EsoCure Esophageal Ablation Device with Patented Caldus Technology to Commercial Product Pipeline

von , 18.02.2020, 14:30 Uhr

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard and EsoCheck products NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced

Meistgelesene Nachrichten

24h 48h 72h 7 Tage 30 Tage 3 Mo 12 Mo 24 Mo